First human test of potential muscle disease treatment
Disease control
Completed
This early-stage study tested the safety of a new drug called PGN-EDODM1 in 24 adults with Myotonic Dystrophy Type 1 (DM1), a genetic muscle-wasting disease. The main goal was to see if single doses given through an IV were safe and well-tolerated. Researchers also measured how t…
Phase: PHASE1 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC